Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
Our study demonstrates that tertiary lymphoid structures (TLS) can form in human glioma, and that agonistic CD40 therapy (αCD40) promotes the formation of TLS in murine glioma models. However, αCD40 also impairs T cell function through the induction of regulatory B cells in the tumor.
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth
We show the importance of hypoxia in activating enzymes that control proper collagen maturation in eye melanoma. Disrupting this process with an inhibitor of the HIF-1/p300 transcription complex leads to disordered collagen structure and reduces tumor growth in the eye and liver in mice xenografts.
Gilteritinib plus CUDC-907 – A Novel Therapeutic Combination with The Ability to Overcome Drug Resistance
In this study, we showed that combining the second-generation FLT3 inhibitor gilteritinib with the dual PI3K/HDAC inhibitor CUDC-907 synergistically improved anti-leukemic activity against FLT3-ITD acute myeloid leukemia (AML) – and that each agent reciprocally overcame resistance to the other drug.
